Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML.
Journal: European journal of haematology
Published: May 27, 2026
Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms.
Journal: Biochemical pharmacology
Published: April 18, 2026
Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2Ar and NPM1-m AML.
Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2Ar and NPM1-m AML.
Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026
Clinical and Molecular Characterization of Myeloid Sarcoma: A Systematic Review and Meta-Analysis.
Journal: Cancers
Published: October 23, 2025
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.
Journal: Hematology (Amsterdam, Netherlands)
Published: October 07, 2025
American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.
Journal: Blood advances
Published: October 06, 2025
Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine.
Journal: Molecular oncology
Published: March 04, 2025
Real world analysis of long-term efficacy of isovolemic red cell exchange in sickle cell disease: a single center experience.
Journal: Blood transfusion = Trasfusione del sangue
Published: January 20, 2025
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.
Journal: Journal of hematology & oncology
Published: November 06, 2024
Last Updated: 09/26/2026